Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
US |
|
W
|
WatosCorea Co Ltd
KOSDAQ:079000
|
KR |
Intrinsic Value
The intrinsic value of Madrigal Pharmaceuticals Inc (MDGL) under the Base Case is 565.26 USD per share.
Compared with the current market price of 436.92 USD, the stock appears
Undervalued by 23% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Madrigal Pharmaceuticals Does
Madrigal Pharmaceuticals is a biopharmaceutical company focused on treating metabolic and liver disease. Its main product is a prescription medicine for adults with noncirrhotic steatohepatitis, a serious form of fatty liver disease now often called MASH. The company does not run a broad drug portfolio; it is centered on this one disease area and the therapy built for it.
- Headquarters
- United States of America US
- Employees
- 915
- IPO date
- Feb 6, 2007
Madrigal Pharmaceuticals has no economic moat
Doctors can choose competing treatments, so Madrigal cannot rely on a captive group of patients or a market that only it can serve. Rezdiffra’s patents protect the drug itself, but do not stop other medicines from treating MASH, and the drug does not become more valuable as more people use it.
Read the full moat analysis
Revenue & Expenses Breakdown
Madrigal Pharmaceuticals Inc
Earnings Waterfall
Madrigal Pharmaceuticals Inc
The intrinsic value for Madrigal Pharmaceuticals Inc (MDGL) under the Base Case is 565.26 USD.
Compared with the current market price of 436.92 USD, the stock appears Undervalued by 23% .